Online Trial Tracker - Larvol Sigma

Trial + Data / Events

Status

Region

Interventions

Sponsor

Conditions

Primary compl

Study compl

azacitidine / Generic mfg.

NCT03684811: A Study of FT-2102 in Patients With Advanced Solid Tumors and Gliomas With an IDH1 Mutation

Completed

1/2

Europe, US, RoW

FT-2102, Azacitidine, Vidaza, Nivolumab, Opdivo, Gemcitabine and Cisplatin, Gemzar and Platinol

Forma Therapeutics, Inc.

Cohort 1a and 1b: Glioma (Advanced Gliomas and Glioblastoma Multiforme), Cohort 2a and 2b: Hepatobiliary Tumors (Hepatocellular Carcinoma, Bile Duct Carcinoma, Intrahepatic Cholangiocarcinoma, Other Hepatobiliary Carcinomas), Cohort 3a and 3b: Chondrosarcoma, Cohort 4a and 4b: Intrahepatic Cholangiocarcinoma, Cohort 5a: Other Non-Central Nervous System Solid Tumors With IDH1 Mutations

05/21

06/22

NCT04648826: Aerosolized Azacytidine as Epigenetic Priming for Bintrafusp Alfa-Mediated Immune Checkpoint Blockade in Patients With Unresectable Pulmonary Metastases From Sarcomas, Germ Cell Tumors, or Epithelial Malignancies

Withdrawn

1/2

AeroEclipse II Breath Actuated Nebulizer, Bintrafusp alfa, Azacytidine

National Cancer Institute (NCI)

Sarcomas, Melanomas, Germ Cell Tumors, Epithelial Malignancies (Excluding Lung and Renal Cell Carcinomas), Pulmonary Metastases

12/21

CA209-9WW, NCT03628209: Nivolumab or Nivolumab and Azacitidine in Patients With Recurrent, Resectable Osteosarcoma

Active, not recruiting

1/2

Nivolumab, Opdivo®, Azacitidine, Vidaza®, Post Treatment Surgery, Standard of Care, Resection of disease

H. Lee Moffitt Cancer Center and Research Institute, Bristol-Myers Squibb

Osteosarcoma, Osteosarcoma in Children, Osteosarcoma Recurrent, Sarcoma

12/24



	Diseases Companies Products Productz Mechanisms of Action Sites